Wall Street brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to post earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Allena Pharmaceuticals’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.59). Allena Pharmaceuticals reported earnings per share of ($3.49) during the same quarter last year, which would indicate a positive year over year growth rate of 86.2%. The firm is scheduled to report its next earnings report on Thursday, December 13th.
Zacks’ EPS calculations are an average based on a survey of analysts that cover Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last released its earnings results on Tuesday, August 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.02).
Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its stake in Allena Pharmaceuticals by 246.4% in the first quarter. Wells Fargo & Company MN now owns 9,336 shares of the company’s stock valued at $103,000 after acquiring an additional 6,641 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Allena Pharmaceuticals in the first quarter valued at approximately $124,000. Rhumbline Advisers acquired a new stake in Allena Pharmaceuticals in the second quarter valued at approximately $133,000. Spark Investment Management LLC acquired a new stake in Allena Pharmaceuticals in the second quarter valued at approximately $208,000. Finally, Acadian Asset Management LLC acquired a new stake in Allena Pharmaceuticals in the second quarter valued at approximately $242,000. Hedge funds and other institutional investors own 84.90% of the company’s stock.
Shares of Allena Pharmaceuticals stock traded down $0.19 during trading on Friday, hitting $10.31. The stock had a trading volume of 26,312 shares, compared to its average volume of 89,339. The company has a market cap of $219.56 million and a P/E ratio of -2.15. The company has a debt-to-equity ratio of 0.15, a current ratio of 29.32 and a quick ratio of 29.32. Allena Pharmaceuticals has a 1 year low of $6.13 and a 1 year high of $17.56.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Article: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.